Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | MH2 domain-containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Loa Loa (eye worm) | transcription factor SMAD2 | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Brugia malayi | MH2 domain containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.0914 | 0.0257 |
Loa Loa (eye worm) | dihydrofolate reductase | 0.0805 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.0914 | 0.0257 |
Echinococcus multilocularis | dihydrofolate reductase | 0.0805 | 1 | 1 |
Schistosoma mansoni | dihydrofolate reductase | 0.0805 | 1 | 1 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.0805 | 1 | 1 |
Chlamydia trachomatis | dihydrofolate reductase | 0.0805 | 1 | 0.5 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.0497 | 0.5332 | 0.5 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.0497 | 0.5332 | 0.5 |
Echinococcus multilocularis | geminin | 0.0205 | 0.0914 | 0.0257 |
Echinococcus granulosus | dihydrofolate reductase | 0.0805 | 1 | 1 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0497 | 0.5332 | 0.5 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.0805 | 1 | 1 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0497 | 0.5332 | 0.5 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.0805 | 1 | 1 |
Brugia malayi | Dihydrofolate reductase | 0.0805 | 1 | 1 |
Onchocerca volvulus | 0.0189 | 0.0675 | 0.5 | |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.0497 | 0.5332 | 0.5 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.0497 | 0.5332 | 0.5 |
Brugia malayi | thymidylate synthase | 0.0189 | 0.0675 | 0.0675 |
Loa Loa (eye worm) | thymidylate synthase | 0.0189 | 0.0675 | 0.0675 |
Echinococcus granulosus | geminin | 0.0205 | 0.0914 | 0.0257 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.1623 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 4.6109 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.